Seeking efficiency in executive compensation benchmarking?

Unlock Efficiency in Executive Compensation Benchmarking with CompAnalyst Executive

CompAnalyst Executive

The charts on this page feature a breakdown of the total annual pay for the top executives at JAZZ PHARMACEUTICALS PLC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. JAZZ PHARMACEUTICALS PLC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. JAZZ PHARMACEUTICALS PLC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Bruce C. Cozadd
Chairperson and CEO
Total Cash $2,413,837 Equity $12,896,545 Other $30,853 Total Compensation $15,341,235
Daniel N. Swisher Jr.
Former President and COO
Total Cash $1,404,869 Equity $4,093,987 Other $30,118 Total Compensation $5,528,974
Neena M. Patil
Executive Vice President and Chief Legal Officer
Total Cash $993,945 Equity $2,865,730 Other $17,760 Total Compensation $3,877,435
Kim Sablich
Former Executive Vice President and General Manager, US
Total Cash $958,939 Equity $3,173,022 Other $33,343 Total Compensation $4,165,304
Renée Galá
President and COO
Total Cash $1,337,719 Equity $4,077,397 Other $19,272 Total Compensation $5,434,388
Robert Iannone M.D., M.S.C.E
Executive Vice President, Global Head of Research and Development
Total Cash $1,170,526 Equity $3,786,999 Other $21,552 Total Compensation $4,979,077
Patricia Carr
Senior Vice President and Chief Accounting Officer (Former Interim Principal Financial Officer)
Total Cash $597,049 Equity $767,623 Other $36,356 Total Compensation $1,401,028
For its 2023 fiscal year, JAZZ PHARMACEUTICALS PLC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Bruce C. Cozadd CEO Pay $15,341,235 Median Employee Pay $234,605 CEO Pay Ratio 65:1
For its 2023 fiscal year, JAZZ PHARMACEUTICALS PLC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Anne O'Riordan Total Cash $523,770
Catherine A. Sohn, Pharm.D. Total Cash $523,770
Heather Ann McSharry Total Cash $543,770
Jennifer E. Cook Total Cash $533,770
Kenneth W. O'Keefe Total Cash $513,770
Mark D. Smith, M.D. Total Cash $521,270
Norbert G. Riedel, Ph.D. Total Cash $533,770
Patrick G. Enright Total Cash $526,270
Peter Gray Total Cash $533,770
Rick E. Winningham Total Cash $571,270
Seamus Mulligan Total Cash $531,270

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.